Cargando…
Anemia and neutrophil-to-lymphocyte ratio are prognostic in p16-positive oropharyngeal carcinoma treated with concurrent chemoradiation
OBJECTIVES: We investigated the prognostic value of pre-treatment hematological parameters in patients with p16-positive oropharyngeal squamous-cell carcinoma (OPSCC). MATERIAL AND METHODS: Neutrophil count, lymphocyte count, neutrophil-to-lymphocyte ratio (NLR), and hemoglobin concentration measure...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5886959/ https://www.ncbi.nlm.nih.gov/pubmed/29253748 http://dx.doi.org/10.1016/j.pvr.2017.12.002 |
_version_ | 1783312196852252672 |
---|---|
author | Gorphe, Philippe Chekkoury Idrissi, Younès Tao, Yungan Schernberg, Antoine Ou, Dan Temam, Stéphane Casiraghi, Odile Blanchard, Pierre Mirghani, Haïtham |
author_facet | Gorphe, Philippe Chekkoury Idrissi, Younès Tao, Yungan Schernberg, Antoine Ou, Dan Temam, Stéphane Casiraghi, Odile Blanchard, Pierre Mirghani, Haïtham |
author_sort | Gorphe, Philippe |
collection | PubMed |
description | OBJECTIVES: We investigated the prognostic value of pre-treatment hematological parameters in patients with p16-positive oropharyngeal squamous-cell carcinoma (OPSCC). MATERIAL AND METHODS: Neutrophil count, lymphocyte count, neutrophil-to-lymphocyte ratio (NLR), and hemoglobin concentration measurement (Hb), were collected on day one of treatment. Endpoints were overall survival (OS) and progression-free survival (PFS). All patients were planned to receive concurrent chemoradiation. Staging were reviewed according to the recent AJCC 8th edition. RESULTS: We included 167 patients in this study. In multivariate analyses, a smoking history > 30 packyears was associated with decreased OS (p = 0.009; HR, 3.4827) and PFS (p = 0.042; HR, 2.421); Hb < 12 g/dL was associated with impaired OS (p = 0.007; HR, 6.527) and PFS (p = 0.014; HR, 4.092); an NLR > 5 before treatment was associated with decreased OS (p = 0.042; HR, 2.945). Hemoglobin concentration and the NLR were not correlated (p = 0.577), nor anemia and an NLR > 5 (p = 0.167). Patients with an NLR > 5 had a significantly higher rate of disease recurrence (30.8% vs. 8.4%, p = 0.0299, RR = 3.922, 95% CI 1.351–11.386). DISCUSSION: We found hemoglobin level and the NLR to be independent prognostic factors in p16-positive OPSCC patients. This approach is to be considered for further clinical investigations, and its significance in treatment decision-making should be further explored. |
format | Online Article Text |
id | pubmed-5886959 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-58869592018-04-11 Anemia and neutrophil-to-lymphocyte ratio are prognostic in p16-positive oropharyngeal carcinoma treated with concurrent chemoradiation Gorphe, Philippe Chekkoury Idrissi, Younès Tao, Yungan Schernberg, Antoine Ou, Dan Temam, Stéphane Casiraghi, Odile Blanchard, Pierre Mirghani, Haïtham Papillomavirus Res Article OBJECTIVES: We investigated the prognostic value of pre-treatment hematological parameters in patients with p16-positive oropharyngeal squamous-cell carcinoma (OPSCC). MATERIAL AND METHODS: Neutrophil count, lymphocyte count, neutrophil-to-lymphocyte ratio (NLR), and hemoglobin concentration measurement (Hb), were collected on day one of treatment. Endpoints were overall survival (OS) and progression-free survival (PFS). All patients were planned to receive concurrent chemoradiation. Staging were reviewed according to the recent AJCC 8th edition. RESULTS: We included 167 patients in this study. In multivariate analyses, a smoking history > 30 packyears was associated with decreased OS (p = 0.009; HR, 3.4827) and PFS (p = 0.042; HR, 2.421); Hb < 12 g/dL was associated with impaired OS (p = 0.007; HR, 6.527) and PFS (p = 0.014; HR, 4.092); an NLR > 5 before treatment was associated with decreased OS (p = 0.042; HR, 2.945). Hemoglobin concentration and the NLR were not correlated (p = 0.577), nor anemia and an NLR > 5 (p = 0.167). Patients with an NLR > 5 had a significantly higher rate of disease recurrence (30.8% vs. 8.4%, p = 0.0299, RR = 3.922, 95% CI 1.351–11.386). DISCUSSION: We found hemoglobin level and the NLR to be independent prognostic factors in p16-positive OPSCC patients. This approach is to be considered for further clinical investigations, and its significance in treatment decision-making should be further explored. Elsevier 2017-12-11 /pmc/articles/PMC5886959/ /pubmed/29253748 http://dx.doi.org/10.1016/j.pvr.2017.12.002 Text en © 2017 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Gorphe, Philippe Chekkoury Idrissi, Younès Tao, Yungan Schernberg, Antoine Ou, Dan Temam, Stéphane Casiraghi, Odile Blanchard, Pierre Mirghani, Haïtham Anemia and neutrophil-to-lymphocyte ratio are prognostic in p16-positive oropharyngeal carcinoma treated with concurrent chemoradiation |
title | Anemia and neutrophil-to-lymphocyte ratio are prognostic in p16-positive oropharyngeal carcinoma treated with concurrent chemoradiation |
title_full | Anemia and neutrophil-to-lymphocyte ratio are prognostic in p16-positive oropharyngeal carcinoma treated with concurrent chemoradiation |
title_fullStr | Anemia and neutrophil-to-lymphocyte ratio are prognostic in p16-positive oropharyngeal carcinoma treated with concurrent chemoradiation |
title_full_unstemmed | Anemia and neutrophil-to-lymphocyte ratio are prognostic in p16-positive oropharyngeal carcinoma treated with concurrent chemoradiation |
title_short | Anemia and neutrophil-to-lymphocyte ratio are prognostic in p16-positive oropharyngeal carcinoma treated with concurrent chemoradiation |
title_sort | anemia and neutrophil-to-lymphocyte ratio are prognostic in p16-positive oropharyngeal carcinoma treated with concurrent chemoradiation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5886959/ https://www.ncbi.nlm.nih.gov/pubmed/29253748 http://dx.doi.org/10.1016/j.pvr.2017.12.002 |
work_keys_str_mv | AT gorphephilippe anemiaandneutrophiltolymphocyteratioareprognosticinp16positiveoropharyngealcarcinomatreatedwithconcurrentchemoradiation AT chekkouryidrissiyounes anemiaandneutrophiltolymphocyteratioareprognosticinp16positiveoropharyngealcarcinomatreatedwithconcurrentchemoradiation AT taoyungan anemiaandneutrophiltolymphocyteratioareprognosticinp16positiveoropharyngealcarcinomatreatedwithconcurrentchemoradiation AT schernbergantoine anemiaandneutrophiltolymphocyteratioareprognosticinp16positiveoropharyngealcarcinomatreatedwithconcurrentchemoradiation AT oudan anemiaandneutrophiltolymphocyteratioareprognosticinp16positiveoropharyngealcarcinomatreatedwithconcurrentchemoradiation AT temamstephane anemiaandneutrophiltolymphocyteratioareprognosticinp16positiveoropharyngealcarcinomatreatedwithconcurrentchemoradiation AT casiraghiodile anemiaandneutrophiltolymphocyteratioareprognosticinp16positiveoropharyngealcarcinomatreatedwithconcurrentchemoradiation AT blanchardpierre anemiaandneutrophiltolymphocyteratioareprognosticinp16positiveoropharyngealcarcinomatreatedwithconcurrentchemoradiation AT mirghanihaitham anemiaandneutrophiltolymphocyteratioareprognosticinp16positiveoropharyngealcarcinomatreatedwithconcurrentchemoradiation |